Preventing harmful protein aggregation
Synthetic Peptides as basis for multifunctional drugs in Parkinson's disease
In Alzheimer's, Parkinson's, and type 2 diabetes, harmful protein aggregates and deposits, known as amyloid plaques, develop. There is also much evidence that these three diseases are interconnected and mutually reinforcing. A research team led by the 91ɫ (TUM) has now shown that synthetic mini-proteins (macrocyclic peptides) developed by the researchers inhibit both amyloid formation in Parkinson's and harmful protein interactions between the three diseases in experimental models. They could serve as the basis for future drugs to treat these diseases.